Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide

Abstract Thalidomide has shown its efficacy in the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT) patients. We hypothetize that, owing to its anti-inflammatory/antiangiogenic/vascular growth maturation properties, thalidomide should be useful in the prophylaxy and therapy of H...

Full description

Saved in:

Bibliographic Details
Published in:	Medical hypotheses Vol. 80; no. 5; pp. 587 - 588
Main Authors:	Lacout, Alexis, Marcy, Pierre Yves, Hajjam, Mostafa El, Lacombe, Pascal
Format:	Journal Article
Language:	English
Published:	United States Elsevier Ltd 01-05-2013
Subjects:	Angiogenesis Inhibitors - therapeutic use Arteriovenous Fistula - drug therapy Arteriovenous Fistula - etiology Arteriovenous Fistula - physiopathology Humans Internal Medicine Models, Biological Neovascularization, Pathologic - etiology Neovascularization, Pathologic - physiopathology Neovascularization, Pathologic - prevention & control Pulmonary Artery - abnormalities Pulmonary Artery - physiopathology Pulmonary Veins - abnormalities Pulmonary Veins - physiopathology Telangiectasia, Hereditary Hemorrhagic - complications Telangiectasia, Hereditary Hemorrhagic - drug therapy Telangiectasia, Hereditary Hemorrhagic - physiopathology Thalidomide - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Thalidomide has shown its efficacy in the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT) patients. We hypothetize that, owing to its anti-inflammatory/antiangiogenic/vascular growth maturation properties, thalidomide should be useful in the prophylaxy and therapy of HHT patients presenting with initial lung involvement.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0306-9877 1532-2777
DOI:	10.1016/j.mehy.2013.01.031